AbbVie, based in North Chicago, Illinois, US, will invest $380 million to build two new API manufacturing facilities at its campus.
Construction starts in spring 2026, with operations set for 2029 and 300 jobs to be created.
The plants will use AI and advanced manufacturing to produce next-generation neuroscience and obesity medicines, reinforcing US pharmaceutical production capacity.